Expert panel raises alarm over deaths linked to Neurocrine's Prader-Willi drug

A group of Prader-Willi syndrome experts has flagged serious side effects and seven deaths potentially tied to Neurocrine Biosciences' Vykat XR. The safety concerns have prompted new warnings for the treatment. The drug's risk-benefit profile is now under heightened scrutiny.